Anebulo Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for acute cannabinoid intoxication.
ANEB | US
Overview
Corporate Details
- ISIN(s):
- US0345691036
- LEI:
- Country:
- United States of America
- Address:
- C/O ANEBULO PHARMACEUTICALS, INC., 78734 LAKEWAY
- Website:
- https://www.anebulo.com/
- Sector:
- Manufacturing
Description
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing therapies for substance use disorders, with a primary focus on acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning. The company's lead investigational candidate, ANEB-001, is a potent, small-molecule cannabinoid receptor antagonist designed to rapidly reverse the symptoms of cannabis overdose. Anebulo aims to address the growing unmet medical need for an antidote to ACI, driven by the increasing legalization of cannabis and a corresponding rise in related emergency department visits, particularly among vulnerable populations like children. The development of ANEB-001 targets a rapid and clinically impactful solution for emergency medical settings.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Anebulo Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Anebulo Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Anebulo Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
